Irritable bowel syndrome affects many, but treatments are few

08/24/2004 | Boston Globe (tiered subscription model), The

With some studies show 10% to 15% of Americans have irritable bowel syndrome, pharmaceutical companies are working to find better treatments for the key symptoms of chronic diarrhea, constipation and cramping. Only two drugs have been approved so far, Zelnorm for constipation and Lotronex for severe diarrhea, and with few other options, some patients are turning to alternative treatments, such as acupuncture.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA